Evidence map›Paper›PMID 31670911›Full record

ArticleCancer medicine2019

Increased risk for other cancers in individuals with Ewing sarcoma and their relatives.

Diana Abbott, Schuyler O'Brien, James M Farnham, Erin L Young, Jeffrey Yap, Kevin Jones, Stephen L Lessnick, R Lor Randall, Joshua D Schiffman, Lisa A Cannon-Albright

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. [Analysis of 41 cases of non-metastatic Ewing's sarcoma in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024
    Article
  3. Review
  4. Article
  5. Primary cutaneous extraskeletal Ewing sarcoma of the plantar region: clinicopathological features and review of the literature.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Diana AbbottGenetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Schuyler O'BrienHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
James M FarnhamGenetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.
Erin L YoungHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Jeffrey YapHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Kevin JonesHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Stephen L LessnickCenter for Childhood Cancer and Blood Diseases at Nationwide Children's Hospital, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, The Ohio State University College of Medicine, Columbus, OH, USA.
R Lor RandallDepartment of Orthopedic Surgery, UC Davis, Sacramento, CA, USA.
Joshua D SchiffmanHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Lisa A Cannon-AlbrightGenetic Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.ORCID 0000-0003-2602-3668
University of Utah · USNationwide Children's Hospital · USUniversity of California Davis Medical Center · US

Funding

UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6M
Training Program in Genomic MedicineT32HG008962 · NHGRI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Lynn Jorde, Aaron R Quinlan · 2016 to 2026
$3.0M
NCI NIH HHS HHSN261201800016CNCI NIH HHS HHSN261201800016INCI NIH HHS P30 CA042014NCI NIH HHS P30 CA42014NHGRI NIH HHS T32 HG008962
6 · The paper itself

Abstract

backgroundThere are few reports of the association of other cancers with Ewing sarcoma in patients and their relatives. We use a resource combining statewide genealogy and cancer reporting to provide unbiased risks.

methodsUsing a combined genealogy of 2.3 million Utah individuals and the Utah Cancer Registry (UCR), relative risks (RRs) for cancers of other sites were estimated in 143 Ewing sarcoma patients using a Cox proportional hazards model with matched controls; however, risks in relatives were estimated using internal cohort-specific cancer rates in first-, second-, and third-degree relatives.

resultsCancers of three sites (breast, brain, complex genotype/karyotype sarcoma) were observed in excess in Ewing sarcoma patients. No Ewing sarcoma patients were identified among first-, second-, or third-degree relatives of Ewing sarcoma patients. Significantly increased risk for brain, lung/bronchus, female genital, and prostate cancer was observed in first-degree relatives. Significantly increased risks were observed in second-degree relatives for breast cancer, nonmelanoma eye cancer, malignant peripheral nerve sheath cancer, non-Hodgkin lymphoma, and translocation sarcomas. Significantly increased risks for stomach cancer, prostate cancer, and acute lymphocytic leukemia were observed in third-degree relatives.

conclusionsThis analysis of risk for cancer among Ewing sarcoma patients and their relatives indicates evidence for some increased cancer predisposition in this population which can be used to individualize consideration of potential treatment of patients and screening of patients and relatives.

Indexed as

FamilyHumansMaleNeoplasms, Second PrimaryPopulation SurveillanceProportional Hazards ModelsRegistriesRisk AssessmentRisk FactorsSarcoma, EwingUtahcancerEwing sarcomarelativerelative riskUPDB

Identifiers

PMID31670911
PMCPMC6912049
OpenAlexW2985997542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.